|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001688,
umls-concept:C0015376,
umls-concept:C0205373,
umls-concept:C0376209,
umls-concept:C0396670,
umls-concept:C0456081,
umls-concept:C0879626,
umls-concept:C0947647,
umls-concept:C1456820,
umls-concept:C1521801,
umls-concept:C2826285
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1995-11-13
|
|
pubmed:abstractText |
The tolerated systemic dose of recombinant tumor necrosis factor alpha (rTNF-alpha) is very limited, since its administration leads to a severe septic shock-like condition. Its implementation in isolated limb perfusion (ILP) for metastatic melanoma or advanced soft-tissue sarcoma confined to the limb facilitates doses of rTNF-alpha 10 times higher than the systemic tolerated dose. However, with the traditional high flow rate used in ILP, systemic leakage and side effects are not eliminated.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0004-0010
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
130
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1079-84
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7575120-Adolescent,
pubmed-meshheading:7575120-Adult,
pubmed-meshheading:7575120-Aged,
pubmed-meshheading:7575120-Analysis of Variance,
pubmed-meshheading:7575120-Antineoplastic Agents,
pubmed-meshheading:7575120-Antineoplastic Agents, Alkylating,
pubmed-meshheading:7575120-Arm,
pubmed-meshheading:7575120-Blood Cell Count,
pubmed-meshheading:7575120-Chemotherapy, Cancer, Regional Perfusion,
pubmed-meshheading:7575120-Cholesterol,
pubmed-meshheading:7575120-Drug Administration Schedule,
pubmed-meshheading:7575120-Female,
pubmed-meshheading:7575120-Hemodynamics,
pubmed-meshheading:7575120-Humans,
pubmed-meshheading:7575120-Leg,
pubmed-meshheading:7575120-Liver Function Tests,
pubmed-meshheading:7575120-Male,
pubmed-meshheading:7575120-Melanoma,
pubmed-meshheading:7575120-Melphalan,
pubmed-meshheading:7575120-Metabolism,
pubmed-meshheading:7575120-Middle Aged,
pubmed-meshheading:7575120-Recombinant Proteins,
pubmed-meshheading:7575120-Sarcoma,
pubmed-meshheading:7575120-Soft Tissue Neoplasms,
pubmed-meshheading:7575120-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
|
|
pubmed:affiliation |
Department of Intensive Care and Anesthesiology, Ichilov Hospital, Tel Aviv, Israel.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
